Stock fact sheet · data as of
InterCure Ltd. (INCR): fair value, margin of safety and Wheel Score
Ticker symbol INCR · Healthcare · Drug Manufacturers - Specialty & Generic · Israel · Speculative
Is INCR undervalued?
At 3.61 (close of 5 Nov 2026), INCR trades 111% over the GLS average fair value of 1.71, with 0 of 1 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
Only 1 of the nine models produced a value (10 Cap); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.
The nightly engine files INCR under Speculative - it is losing money or its Piotroski health score is 3 or lower - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for INCR
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 1.71 | -53% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 0.6026 | -83% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: INCR passes 4 of the nine Piotroski tests. Our scans drop the stock at the health filter; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.3 out of 10: returns on capital, margins or the balance sheet have not shown a lasting edge yet - often a young company, a thin-margin business or one that has only recently turned profitable.
Returns on capital are thin or negative - ROIC -6.2%, ROE -9.0%, ROA -5.2% - with debt at 0.46 times equity and a free-cash-flow yield of 6.2%.
InterCure Ltd. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | -6.2% |
|---|---|---|---|
| GLS Moat | 1.3 / 10 | ROE | -9.0% |
| Debt / equity | 0.46 | ROA | -5.2% |
| Free-cash-flow yield | 6.2% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 13: Weak
INCR scores 13 out of 100 on the Wheel Score, in the Weak band (under 50): it fails filter 1, options that actually trade - options too quiet (120 open interest, 63 a day); and filter 2, a real business, not a gamble - speculative (a loss, or a weak Piotroski score); and filter 3, below fair value - trades 111% above our fair value; and filter 4, financially healthy - Piotroski 4/9 (under 6); and filter 5, can repay its debt - 3.5 years to repay its debt (over 3); and filter 7, a premium worth selling - implied volatility 142% (over 80%); and filter 8, big enough - market cap $43M (under $1.0B); and filter 9, not a penny stock - price 3.61 (under $5), and the parts are thin too - value weak, premium weak, moat weak, health fair, red flags fair, option trading weak, stability fair. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.
Implied volatility is 142%, above the 80% ceiling of the Wheel Trade Filter on premium. The premium looks generous, but moves of that size can blow through any strike. Chain open interest is thin - 120 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.
Volume runs at 6k shares a day on a market cap of $43M, with a beta of 0.64 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | options too quiet (120 open interest, 63 a day) |
| 2 | A real business, not a gamble | Fails | speculative (a loss, or a weak Piotroski score) |
| 3 | Below fair value | Fails | trades 111% above our fair value |
| 4 | Financially healthy | Fails | Piotroski 4/9 (under 6) |
| 5 | Can repay its debt | Fails | 3.5 years to repay its debt (over 3) |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Fails | implied volatility 142% (over 80%) |
| 8 | Big enough | Fails | market cap $43M (under $1.0B) |
| 9 | Not a penny stock | Fails | price 3.61 (under $5) |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Weak | 111% above fair value | |
| Premium | Weak | implied volatility 142% | |
| Moat | Weak | moat 1.3/10 | |
| Health | Fair | Piotroski 4/9 | |
| Red Flags | Fair | Red Flags score 75/100 | |
| Option trading | Weak | 63 contracts a day, 120 open interest | |
| Stability | Fair | beta 0.64, $43M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for INCR in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to InterCure Ltd. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| TLPH Talphera, Inc. | 1.05 | - | - | 13Weak | $55M |
| RMTI Rockwell Medical, Inc. | 8.05 | 9.84 | +18% | 17Weak | $32M |
| RAPH Raphael Pharmaceutical Inc. | 1.51 | - | - | 8No options | $30M |
| HSTI High Sierra Technologies, Inc. | 1.40 | - | - | 11No options | $29M |
| ZYBT Zhengye Biotechnology Holding Limited | 1.37 | 1.27 | -7% | 13No options | $65M |
| CPIX Cumberland Pharmaceuticals Inc. | 4.44 | 22.07 | +80% | 26Weak | $67M |
| CPHI China Pharma Holdings, Inc. | 0.5875 | - | - | 12No options | $25M |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | 5.21 | - | - | 10No options | $25M |
| AAWH Ascend Wellness Holdings, Inc. | 0.3950 | 4.21 | +91% | 25No options | $80M |
| TXMD TherapeuticsMD, Inc. | 1.82 | 5.39 | +66% | 28Weak | $21M |
| AYTU Aytu BioPharma, Inc. | 1.92 | 5.29 | +64% | 28No options | $21M |
| HYEX Healthy Extracts Inc. | 1.40 | 0.6122 | -129% | 12No options | $21M |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about INCR
Is INCR undervalued right now?
No: at 3.61 the stock trades 111% above the GLS average fair value of 1.71 (data as of 5 Nov 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of INCR and what does it mean?
INCR scores 13 out of 100 (Weak) - it fails Wheel Trade Filters 1, 2, 3, 4, 5, 7, 8, 9. The Wheel Score ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned - in two parts: the 9 pass/fail Wheel Trade Filters (busy options, a real business, below fair value, Piotroski 6 or more, debt it can repay, a Red Flags score of 60 or more, implied volatility of 25-80%, a $1 billion company, $5 a share) and a ranking of how strongly a stock passes on value, premium, moat, health, red flags, option trading and stability. A stock that fails any filter stays under 70; 70-84 is Good, 85 and above is Prime. The Sunday Scan is the top 10 that pass, sorted by Wheel Score.
What is the GLS fair value for INCR?
1.71 per share as of 5 Nov 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does InterCure Ltd. report earnings next?
No upcoming earnings date is recorded for INCR in our calendar as of 5 Nov 2026; the Calendars page is refreshed every morning.
Does INCR have listed options, and how liquid are they?
Yes. The nightly snapshot found 16 listed contracts with 120 open interest across all expiries and implied volatility of 142% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.